Exagen (XGN) Liabilities and Shareholders Equity (2018 - 2026)

Exagen has reported Liabilities and Shareholders Equity for 9 years, with the latest figure at $52.0 million in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity rose 28.94% year-over-year to $52.0 million; the trailing twelve-month figure through Mar 2026 stood at $231.6 million (up 30.17% YoY), and the FY2025 full-year result was $58.0 million, up 29.84% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $52.0 million, down from $58.0 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $122.0 million in Q1 2022, with the low at $40.3 million in Q1 2025.
• Historically, Liabilities and Shareholders Equity has averaged $67.0 million across 5 years, with a median of $58.8 million in 2025.
• Annual changes were most pronounced in 2023 — Liabilities and Shareholders Equity sank 40.03% — and 2025, when it jumped 44.07%.
• Exagen's Liabilities and Shareholders Equity stood at $86.2 million in 2022, then sank by 33.96% to $56.9 million in 2023, then retreated by 21.52% to $44.7 million in 2024, then increased by 29.84% to $58.0 million in 2025, then retreated by 10.45% to $52.0 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $52.0 million (Q1 2026), $58.0 million (Q4 2025), and $62.8 million (Q3 2025), per Business Quant data.